Metabolism-dependent stimulation of reactive oxygen species and DNA synthesis by cyclosporin A in rat smooth muscle cells

Free Radical Biology and Medicine

Volumn 27, Issue 11-12, 1999, Pages 1267-1275

  Nguyen, Nathalie S D ^a   Cottet Maire, Florence ^a   Buetler, Timo M ^a   Lo Russo, Alexandre ^a   Krauskopf, Alexandra S ^a   Armstrong, John M ^b   Vickers, Alison E M ^b   MacÉ, Katherine ^c   Rüegg, Urs T ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

Cyclosporin A; Cytochrome P 450; DNA synthesis; Free radical; Hydroxyl radical; NADPH reductase; Superoxide

Indexed keywords

CHELATING AGENT; CYCLOSPORIN A; DEFEROXAMINE MESYLATE; DIETHYLDITHIOCARBAMIC ACID; FREE RADICAL; HYDROXYL RADICAL; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; REACTIVE OXYGEN METABOLITE; TROLEANDOMYCIN;

ANIMAL CELL; AORTA MEDIA; ARTICLE; DNA SYNTHESIS; DRUG METABOLISM; ELECTRON TRANSPORT; FLUORESCENCE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER;

ANIMALS; AORTA; ARYL HYDROCARBON HYDROXYLASES; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEFEROXAMINE; DITIOCARB; DNA; ENZYME INHIBITORS; FLUORESCENT DYES; MALE; MUSCLE, SMOOTH, VASCULAR; OXIDATION-REDUCTION; OXIDOREDUCTASES, N-DEMETHYLATING; PROTEIN KINASE C; RATS; RATS, INBRED WKY; REACTIVE OXYGEN SPECIES; RNA, MESSENGER;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0033453989     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(99)00160-4     Document Type: Article

References (66)

1. Borel J.F., Baumann G., Chapman I., Donatsch P., Fahr A., Mueller E.A., Vigouret J.M. In vivo pharmacological effects of ciclosporin and some analogues. Adv. Pharmacol. 35:1996;115-246.
2. Kahan B.D. Cyclosporine. New Engl. J. Med. 321:1989;1725-1738.
3. Mason J. Pharmacology of cyclosporine (Sandimmune). VII. Pathophysiology and toxicology of cyclosporine in humans and animals. Pharmacol. Rev. 41:1990;423-434.
4. Textor S.C., Canzanello V.J., Taler S.J., Wilson D.J., Schwartz L.L., Augustine J.E., Raymer J.M., Romero J.C., Wiesner R.H., Krom R.A. Cyclosporine-induced hypertension after transplantation. Mayo Clinic Proc. 69:1994;1182-1193.
5. Lamb F.S., Webb R.C. Cyclosporine augments reactivity of isolated blood vessels. Life Sci. 40:1987;2571-2578.
6. Rego A., Vargas R., Suarez K.R., Foegh M.L., Ramwell P.W. Mechanism of cyclosporin potentiation of vasoconstriction of the isolated rat mesenteric arterial bed role of extracellular calcium . J. Pharmacol. Exp. Ther. 254:1990;799-808.
7. Avdonin P.V., Cottet-Maire F., Afanasjeva G.V., Loktionova S.A., Lhote P., Rüegg U.T. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int. 55:1999;2407-2414.
8. Ahmed S.S., Strobel H.W., Napoli K.L., Grevel J. Adrenochrome reaction implicates oxygen radicals in metabolism of cyclosporine A and FK-506 in rat and human liver microsomes. J. Pharmacol. Exp. Ther. 265:1993;1047-1054.
9. Wolf A., Clemann N., Frieauff W., Ryffel B., Cordier A. Role of reactive oxygen formation in the cyclosporin-A-mediated impairment of renal functions. Transplant. Proc. 26:1994;2902-2907.
10. Wang C., Salahudeen A.K. Lipid peroxidation accompanies cyclosporine nephrotoxicity effects of vitamin E . Kidney Int. 47:1995;927-934.
11. Lopez-Ongil S., Hernandez-Perera O., Navarro-Antolin J., Perez de Lema G., Rodriguez-Puyol M., Lamas S., Rodriguez-Puyol D. Role of reactive oxygen species in the signalling cascade of cyclosporine A-mediated up-regulation of eNOS in vascular endothelial cells. Br. J. Pharmacol. 124:1998;447-454.
12. Yang Z.W., Zheng T., Zhang A., Altura B.T., Altura B.M. Mechanisms of hydrogen peroxide-induced contraction of rat aorta. Eur. J. Pharmacol. 344:1998;169-181.
13. Schreck R., Rieber P., Baeuerle P.A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 10:1991;2247-2258.
14. 2 for platelet-derived growth factor signal transduction. Science. 270:1995;296-299.
15. Sundaresan M., Yu Z.X., Ferrans V.J., Sulciner D.J., Gutkind J.S., Irani K., Goldschmidt-Clermont P.J., Finkel T. Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem. J. 318:1996;379-382.
16. Schreck R., Bauerle A. A role for oxygen radicals as second messengers. Trends Cell Biol. 1:1991;39-43.
17. Kronbach T., Fischer V., Meyer U.A. Cyclosporine metabolism in human liver identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs . Clin. Pharmacol. Ther. 43:1988;630-635.
18. Copeland K.R., Yatscoff R.W., McKenna R.M. Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance. Clin. Chem. 36:1990;225-229.
19. Peterson J.A., White R.E., Yasukochi Y., Coomes M.L., O'Keeffe D.H., Ebel R.E., Masters B.S., Ballou D.P., Coon M.J. Evidence that purified liver microsomal cytochrome P-450 is a one-electron acceptor. J. Biol. Chem. 252:1977;4431-4434.
20. Walker R.J., Lazzaro V.A., Duggin G.G., Horvath J.S., Tiller D.J. Evidence that alterations in renal metabolism and lipid peroxidation may contribute to cyclosporine nephrotoxicity. Transplantation. 50:1990;487-492.
21. Serino F., Grevel J., Napoli K.L., Kahan B.D., Strobel H.W. Generation of oxygen free radicals during the metabolism of cyclosporine A a cause-effect relationship with metabolism inhibition . Mol. Cell Biochem. 122:1993;101-112.
22. Serino F., Grevel J., Napoli K.L., Kahan B.D., Strobel H.W. Oxygen radical formation by the cytochrome P450 system as a cellular mechanism for cyclosporine toxicity. Transplant. Proc. 26:1994;2916-2917.
23. Kuthan H., Tsuji H., Graf H., Ullrich V. Generation of superoxide anion as a source of hydrogen peroxide in a reconstituted monooxygenase system. FEBS Lett. 91:1978;343-345.
24. Roerig D.L., Mascaro L. Jr, Aust S.D. Microsomal electron transport tetrazolium reduction by rat liver microsomal NADPH-cytochrome c reductase . Arch. Biochem. Biophys. 153:1972;475-479.
25. Prough R.A., Masters B.S. Studies on the NADPH oxidase reaction of NADPH-cytochrome c reductase. I. The role of superoxide anion. Ann. N.Y. Acad. Sci. 212:1973;89-93.
26. Rashba-Step J., Cederbaum A.I. Generation of reactive oxygen intermediates by human liver microsomes in the presence of NADPH or NADH. Mol. Pharmacol. 45:1994;150-157.
27. Humes H.D., Jackson N.M., O'Connor R.P., Hunt D.A., White M.D. Pathogenetic mechanisms of nephrotoxicity insights into cyclosporine nephrotoxicity . Transpl. Proc. 17:1985;51-62.
28. Jackson C.L., Schwartz S.M. Pharmacology of smooth muscle cell replication. Hypertension. 20:1992;713-736.
29. Ross R. The pathogenesis of atherosclerosis a perspective for the 1990s . Nature. 362:1993;801-809.
30. Lo Russo A., Passaquin A.C., André P., Skutella M., Rüegg U.T. Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction possible lack of relationship to immunosuppressive activity . Br. J. Pharmacol. 118:1996;885-892.
31. Vickers A.E., Fischer V., Connors S., Fisher R.L., Baldeck J.P., Maurer G., Brendel K. Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metabol. Disp. 20:1992;802-809.
32. Vickers A.E., Jimenez R.M., Spaans M.C., Pflimlin V., Fisher R.L., Brendel K. Human and rat lung biotransformation of cyclosporin A and its derivatives using slices and bronchial epithelial cells. Drug Metabol. Disp. 25:1997;873-880.
33. Debri K., Boobis A.R., Davies D.S., Edwards R.J. Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem. Pharmacol. 50:1995;2047-2056.
34. Oya Y., Yamamoto K., Tonomura A. The biological activity of hydrogen peroxide. I. Induction of chromosome-type aberrations susceptible to inhibition by scavengers of hydroxyl radicals in human embryonic fibroblasts. Mutat. Res. 172:1986;245-253.
35. Henderson L.M., Chappell J.B. Dihydrorhodamine 123 a fluorescent probe for superoxide generation? Eur. J. Biochem. 217:1993;973-980.
36. 2 in cultured endothelial cells. Arch. Biochem. Biophys. 302:1993;348-355.
37. Heikkila R.E., Cabbat F.S., Cohen G. Inactivation of superoxide dismutase by several thiocarbamic acid derivatives. Experientia. 34:1978;1553-1554.
38. Takeuchi K., Takehara K., Ohuchi T. Diethyldithiocarbamate, a superoxide dismutase inhibitor, reduces indomethacin-induced gastric lesions in rats. Digestion. 57:1996;201-209.
39. Ischiropoulos H., Gow A., Thom S.R., Kooy N.W., Royall J.A., Crow J.P. Detection of reactive nitrogen species using 2,7-dicholordihydrofluorescein and dihydrorhodamine 123. Packer L. Methods in enzymology oxygen radicals in biological systems, Part D . 1999;367-373 Academic Press, San Diego.
40. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56:1991;1441-1444.
41. Van Reyk D.M., Dean R.T. The iron-selective chelator desferal can reduce chelated copper. Free Rad. Res. 24:1996;55-60.
42. Roberfroid M., Calderon P.B. Free radicals and oxidation phenomena in biological systems. 1995;Marcel Dekker Inc, New York.
43. Walker R.J., Lazzaro V.A., Duggin G.G., Horvath J.S., Tiller D.J. Structure-activity relationships of cyclosporines. Inhibition of angiotensin II-stimulated prostaglandin release in cultured rat mesangial cells. Transplantation. 50:1990;343-345.
44. Wender P.A., Koehler K.F., Sharkey N.A., Dell'Aquila M.L., Blumberg P.M. Analysis of the phorbol ester pharmacophore on protein kinase C as a guide to the rational design of new classes of analogs. Proc. Natl. Sci. USA. 83:1986;4214-4218.
45. Aihara H., Asaoka Y., Yoshida K., Nishizuka Y. Sustained activation of protein kinase C is essential to HL-60 cell differentiation to macrophage. Proc. Natl. Sci. USA. 88:1991;11062-11066.
46. Kribben A., Wieder E.D., Li X., Van Putten V., Granot Y., Schrier R.W., Nemenoff R.A. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. Am. J. Physiol. 265:1993;C939-C945.
47. Molloy C.J., Taylor D.S., Weber H. Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells. J. Biol. Chem. 268:1993;7338-7345.
48. Puri P.L., Avantaggiati M.L., Burgio V.L., Chirillo P., Collepardo D., Natoli G., Balsano C., Levrero M. Reactive oxygen intermediates mediate angiotensin II-induced c-Jun. c-Fos heterodimer DNA binding activity and proliferative hypertrophic responses in myogenic cells. J. Biol. Chem. 270:1995;22129-22134.
49. Malarkey K., Belham C.M., Paul A., Graham A., Mclees A., Scott P.H., Plevin R. The regulation of tyrosine kinase signalling pathways by growth factor and G-protein coupled receptors. Biochem. J. 309:1995;361-375.
50. Mason J. The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr. Nephrol. 4:1990;554-574.
51. Murray M., Reidy G.F. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev. 42:1990;85-101.
52. McNeil C.M., Murray M. Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic antidepressant drug desipramine and its primary oxidized metabolites. Biochem. Pharmacol. 51:1996;15-20.
53. Reidy G.F., Mehta I., Murray M. Inhibition of oxidative drug metabolism by orphenadrine in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics . Mol. Pharmacol. 35:1989;736-743.
54. Nadler S.G., Strobel H.W. Role of electrostatic interactions in the reaction of NADPH-cytochrome P-450 reductase with cytochromes P-450. Arch. Biochem. Biophys. 261:1988;418-429.
55. Pessayre D. Effects of macrolide antibiotics on drug metabolism in rats and in humans. Int. J. Clin. Pharmacol. Res. 3:1983;449-458.
56. Murray M. P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clin. Pharmacokinet. 23:1992;132-146.
57. Tassaneeyakul W., Birkett D.J., Veronese M.E., McManus M.E., Tukey R.H., Quattrochi L.C., Gelboin H.V., Miners J.O. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265:1993;401-407.
58. Bourrie M., Meunier V., Berger Y., Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996;321-332.
59. Tavares P., Martinez-Salgado C., Eleno N., Teixeira F., Lopez N.J. Effect of cyclosporin A on rat smooth-muscle cell proliferation. J. Cardiol. Pharmacol. 31:1998;46-49.
60. Huang H.C., Lai M.W., Wang H.R., Chung Y.L., Hsieh L.M., Chen C.C. Antiproliferative effect of esculetin on vascular smooth muscle cells possible roles of signal transduction pathways . Eur. J. Pharmacol. 237:1993;39-44.
61. Sellmayer A., Uedelhoven W.M., Weber P.C., Bonventre J.V. Endogenous non-cyclooxygenase metabolites of arachidonic acid modulate growth and mRNA levels of immediate-early response genes in rat mesangial cells. J. Biol. Chem. 266:1993;3800-3807.
62. Forgue-Lafitte M.E., Coudray A.M., Fagot D., Mester J. Effects of ketoconazole on the proliferation and cell cycle of human cancer cell lines. Cancer Res. 52:1992;6827-6831.
63. Li P.F., Dietz R., von Harsdorf R. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation. 96:1997;3602-3609.
64. Janssen Y.M., Van Houten B., Borm P.J., Mossman B.T. Cell and tissue responses to oxidative damage. Lab. Invest. 69:1993;261-274.
65. Kumano K., Chen J., He M., Endo T., Masaki Y. Role of endothelin in FK 506-induced renal hypoperfusion in rats. Transplant. Proc. 27:1995;550-553.
66. Stamler J.S. Redox signaling nitrosylation and related target interactions of nitric oxide . Cell. 78:1994;931-936.